Elutia Inc (ELUT) Stock Price, Quote & News

Company Profile

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcom...

Industry: Medical Devices

Sector: Healthcare

Phone: 240 247 1170

Fax: 408 734 2629

Website: elutia.com

Address:

12510 Prosperity Drive, Suite 370, Silver Spring, United States

Greenpa Sep. 20 at 9:08 PM

$ELUT In the HCW conference, the CEO failed to address the two most critical and questions: (1) what will be the new cash burn rate after the sale and (2) how much cash might be left after debt paid off and remaining litigation settled. How could the CEO not address that?

0 · Reply

stockbot1234 Sep. 19 at 3:11 PM

$ELUT time for shorts to lock 50% profit!!

0 · Reply

stockbot1234 Sep. 19 at 3:10 PM

$ELUT hourly MACD about to cross which is a super bullish sign of reversal!

0 · Reply

stockbot1234 Sep. 19 at 2:59 PM

$ELUT BUY 🚨! Stock has been beaten from $2.42 to $1.06 with 8 red days in a row!! Way oversold and selling is drying up! Can see easy reversal to $1.5-$2 from these levels shortly!! Stock has never done an R/S so these are the lowest levels all time! It has a history of bouncing from $1.1 back to $2!! The BOT🚀 is loaded!!

0 · Reply

Aboudouh Sep. 19 at 7:53 AM

$ELUT

0 · Reply

Sgt_Soju Sep. 17 at 5:20 PM

$ELUT not adding anymore until this thing pops.

0 · Reply

StockGuru95 Sep. 17 at 10:45 AM

$ELUT 👀 2+ highly likely

0 · Reply

ItTakesItAll Sep. 17 at 9:04 AM

$ELUT Adding 1.10-1.30s, oversold

0 · Reply

DARKP00L Sep. 16 at 12:14 PM

$ELUT 08:12 on Sep. 16 2025 Elutia Releases Data In Frontiers In Cardiovascular Medicine Showing That Its Biologic Envelope For Cardiac Implantable Electronic Devices Reduces Bacterial Colonization, Promotes Tissue Remodeling, And Improves Procedural Ease. Patients With The Biologic ECM Envelope Experienced 43% Lower Procedural Difficulty Compared To Those Without Or With Non-Biologic Envelopes #tradeideas

0 · Reply

DARKP00L Sep. 16 at 12:12 PM

0 · Reply

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation

Sep 9, 2025, 8:30 AM EDT - 11 days ago

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

Sep 4, 2025, 8:00 AM EDT - 16 days ago

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

Aug 27, 2025, 8:00 AM EDT - 24 days ago

Elutia to Participate in Upcoming Investor Conferences

Aug 14, 2025, 9:03 PM EDT - 5 weeks ago

Elutia Inc. (ELUT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:05 PM EDT - 5 weeks ago

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

Jul 31, 2025, 4:05 PM EDT - 7 weeks ago

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Jul 31, 2025, 8:00 AM EDT - 7 weeks ago

Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award

Jul 1, 2025, 8:00 AM EDT - 2 months ago

New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices

Jun 26, 2025, 8:00 AM EDT - 3 months ago

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

May 28, 2025, 8:00 AM EDT - 4 months ago

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

May 11, 2025, 7:32 AM EDT - 4 months ago

Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 4 months ago

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

May 1, 2025, 4:05 PM EDT - 5 months ago

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

May 1, 2025, 8:00 AM EDT - 5 months ago

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

Apr 22, 2025, 4:05 PM EDT - 5 months ago

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

Apr 21, 2025, 8:00 AM EDT - 5 months ago

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

Apr 14, 2025, 8:00 AM EDT - 5 months ago

Elutia Confirms No Material Impact from Global Tariffs

Apr 2, 2025, 4:05 PM EDT - 6 months ago

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Mar 25, 2025, 4:05 PM EDT - 6 months ago

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

Mar 6, 2025, 6:22 PM EST - 7 months ago

Elutia Inc. (ELUT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:05 PM EST - 7 months ago

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Feb 20, 2025, 4:05 PM EST - 7 months ago

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Feb 3, 2025, 6:30 AM EST - 8 months ago

Elutia Announces $15.0 Million Registered Direct Offering

Nov 14, 2024, 8:11 PM EST - 11 months ago

Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 4:05 PM EDT - 11 months ago

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices

Sep 6, 2024, 4:23 PM EDT - 1 year ago

Elutia Celebrates First Year

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD EUDA GDTC GOSS GOVX IMRN

Aug 10, 2024, 7:27 AM EDT - 1 year ago

Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

Jun 17, 2024, 8:01 AM EDT - 1 year ago

Elutia Announces $13.26 Million Registered Direct Offering

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

May 12, 2024, 12:21 PM EDT - 1 year ago

Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

Mar 7, 2024, 8:43 PM EST - 1 year ago

Elutia, Inc. (ELUT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:05 PM EST - 1 year ago

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

Feb 22, 2024, 4:05 PM EST - 1 year ago

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

Jan 10, 2024, 4:05 PM EST - 1 year ago

Elutia Regains Compliance with Nasdaq Listing Requirements

Nov 17, 2023, 12:30 PM EST - 2 years ago

Elutia, Inc. (ELUT) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 2 years ago

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

Nov 9, 2023, 8:30 AM EST - 2 years ago

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

Nov 6, 2023, 4:05 PM EST - 2 years ago

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Sep 20, 2023, 8:30 AM EDT - 2 years ago

Elutia to Participate in a Panel Discussion at the Cantor Global Healthcare Conference

Sep 19, 2023, 8:36 AM EDT - 2 years ago

Elutia Announces Private Placement for Proceeds Up to $26 Million

Sep 18, 2023, 4:08 PM EDT - 2 years ago

Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

Sep 8, 2023, 8:30 AM EDT - 2 years ago

Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Greenpa Sep. 20 at 9:08 PM

0 · Reply

stockbot1234 Sep. 19 at 3:11 PM

$ELUT time for shorts to lock 50% profit!!

0 · Reply

stockbot1234 Sep. 19 at 3:10 PM

$ELUT hourly MACD about to cross which is a super bullish sign of reversal!

0 · Reply

stockbot1234 Sep. 19 at 2:59 PM

0 · Reply

Aboudouh Sep. 19 at 7:53 AM

$ELUT

0 · Reply

Sgt_Soju Sep. 17 at 5:20 PM

$ELUT not adding anymore until this thing pops.

0 · Reply

StockGuru95 Sep. 17 at 10:45 AM

$ELUT 👀 2+ highly likely

0 · Reply

ItTakesItAll Sep. 17 at 9:04 AM

$ELUT Adding 1.10-1.30s, oversold

0 · Reply

DARKP00L Sep. 16 at 12:14 PM

0 · Reply

DARKP00L Sep. 16 at 12:12 PM

0 · Reply

willem Sep. 11 at 2:01 PM

$ELUT please explain why $88 Million sale is such a bad thing. That is unless they now have no future?

2 · Reply

Greenpa Sep. 10 at 5:35 PM

$ELUT so much for the strategic relationship with Boston Scientific touted by Mills. He probably destroyed all trust from many existing equity holders. What a joke. I was warned fortunately by a surgeon. I owned for a matter of days. Glad I abandoned. Sorry to those who were duped.

0 · Reply

Greenpa Sep. 10 at 9:12 AM

$ELUT cash will be used to pay off debt and hopefully litigation exposure. The paltry sales proceeds validates my concerns that Mills was exaggerating the value of Elupro.

0 · Reply